Hemiplegic Migraine Market Research Report - Forecast till 2023

Hemiplegic Migraine Market Research Report by Type (Familial, Sporadic), by Treatment (Acute, Preventive), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), by End-user (Hospitals & Clinics, Diagnostic Centres, Others), and Region - Forecast till 2027

ID: MRFR/HC/5250-HCR | | Region: Bric | 110 pages

Hemiplegic Migraine Market Overview:


Hemiplegic migraine, although a rare type of migraine its symptoms are almost same as other migraines.  Intense and throbbing pain, nausea, and sensitivity to light and sound are some of the symptoms caused by hemiplegic migraine. “Hemiplegia” means paralysis and people suffering from it literally feel temporary symptoms of paralysis such as temporary weakness, numbness and tingling, and paralysis on one side of the body which start before the headache.


Although the hemiplegic migraine is considered as a rare disorder affecting a small number of people, over the past few years, the prevalence of hemiplegic migraine has been increasing. Out of the two types of hemiplegic migraine, familial hemiplegic migraine (FHM) is a hereditary condition that affects at least two close relatives in the same family.  


Whereas, the other type, sporadic hemiplegic migraine (SHM) can affect anyone even those who don’t have any family history of the condition. Factors such as changing lifestyle, environmental changes, pollutions, etc. are causes behind the occurrence of SHM. As a result, sporadic hemiplegic migraine is more prevalent than FHM.


However, there are a number of treatment methods available to treat both the types of hemiplegic migraines owing to the technological advancements that happened in the field of medical science in the recent years. Growing prevalence and the availability of treatments are the two key driving forces behind the hemiplegic migraine market growth of hemiplegic migraines.


Considering all these factors, the hemiplegic migraine market is expected to reach approximately 1008 MN USD by the end of 2023, growing at a CAGR of approximately 3.3% during the forecast period (2018-2023). In 2017, the hemiplegic migraine market had valued at USD 830 Million.


Segments


The hemiplegic migraine market has been segmented on the basis of type, treatment, preventive treatment, distribution channel, end-user, and region. By type, the hemiplegic migraine market is segmented into familial hemiplegic migraine and sporadic hemiplegic migraine. By end-user, the hemiplegic migraine market is segmented into hospitals & clinics, diagnostic centers, and others.


By treatment, the hemiplegic migraine market is segmented into acute treatment, triptans, ergotamines, nsaids, antiemetics, narcotic analgesics, and others. By preventive treatment, the hemiplegic migraine market is segmented into antidepressants, botox injections, and others. By distribution channel, the hemiplegic migraine market is segmented into retail pharmacies, hospital pharmacies, online pharmacies, and others. By region, the hemiplegic migraine market is segmented into the Americas, Europe, Asia Pacific, and the Middle East & Africa.


Regional analysis


The Americas accounts for the leading market due to the higher health care expenditures. The fastest uptake of new technologies in the growing healthcare sector is a major driving force driving the hemiplegic migraine market. The presence of well-established market players is fuelling the market.


The market in the European region stands at the second position in terms of the market size owing to the well-established healthcare sector. Also, high per capita healthcare expenditures play a vital role in the hemiplegic migraine market growth.


Whereas, the Asia Pacific region is expected to grow rapidly due to the emerging economies such as China and India.


In Gulf nations, particularly, Saudi Arabia and UAE drive the Middle Eastern & African market. The African region is estimated to witness moderate growth owing to poor economic & political conditions and inadequate healthcare facilities.


Key Players


Some of the market leaders profiled in the report are Abbott Laboratories, Allergan Plc., AstraZeneca, Eisai Co., Ltd., Endo International Plc., GlaxoSmithKline Plc., Impax Laboratories, Eli Lily and Company, Johnson & Johnson, and Merck & Co.


Research Methodology


The research report - Hemiplegic Migraine Market by Market Research Future comprises an in-depth primary research and the detailed analysis of qualitative as well as quantitative aspects of various industry experts. The detailed market analysis gives a clear picture of the current market scenarios including past and future market size in terms of value as well as volume alongside the technological advancement, macroeconomy, and governing factors of the market. The report provides detailed information and strategies of topnotch players in the market while providing a broad study of the market and its various segments in the outlined regions.


Hemiplegic Migraine Market by Type



  • Familial Hemiplegic Migraine

  • Sporadic Hemiplegic Migraine 


Hemiplegic Migraine Market by Treatment



  • Acute treatment

  • Triptans

  • Ergotamines

  • NSAIDS

  • Antiemetics

  • Narcotic Analgesics

  • Others


Hemiplegic Migraine Market by End-user



  • Hospitals & Clinics

  • Diagnostic Centers

  • Others 


Hemiplegic Migraine Market by Preventive Treatment



  • Antidepressants

  • Botox Injections

  • Others


Hemiplegic Migraine Market by Distribution Channel



  • Retail Pharmacies

  • Hospital Pharmacies

  • Online Pharmacies 


Region



  • Americas

    • The U.S.

    • Canada




    • North America

    • South America




  • Europe

    • France

    • The U.K.

    • Germany

    • Italy

    • Spain

    • Rest of Western Europe




    • Western Europe

    • Eastern Europe




  • Asia Pacific


    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia Pacific




Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2023: USD 1008 Million
  • 2027: Significant Value
  •   CAGR   3.3% (2018-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Basis of type, Treatment, Preventive Treatment, Distribution channel, End-user
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Abbott Laboratories, Allergan Plc., AstraZeneca, Eisai Co., Ltd., Endo International Plc., GlaxoSmithKline Plc., Impax Laboratories, Eli Lily and Company, Johnson & Johnson, and Merck & Co
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Growing prevalence
  • The availability of treatments


  • Frequently Asked Questions (FAQ) :


    Hemiplegic migraine market projected to grow at a 3.3% CAGR between 2018-2023.

    Hemiplegic migraine market is predicted to touch USD 1008 million by 2023.

    The Americas is expected to lead the hemiplegic migraine market.

    Environmental changes and rising prevalence of hemiplegic migraine are the key factors driving the hemiplegic migraine market.

    Side effects may limit the hemiplegic migraine market.

    Table of Contents:


    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Hemplegic Migraine Market, by Type

    6.1 Introduction

    6.2 Familial Hemiplegic Migraine

    Market Estimates & Forecast by region, 2020-2027

    Market Estimates & Forecast country, 2020-2027

    6.3 Sporadic Hemiplegic Migraine

    Market Estimates & Forecast by region, 2020-2027

    Market Estimates & Forecast country, 2020-2027

    Chapter 7. Global Hemplegic Migraine Market, By Treatment

    7.1 Introduction

    7.2 Acute Treatment

    7.2.1 Triptans

    Market Estimates & Forecast by region, 2020-2027

    Market Estimates & Forecast country, 2020-2027

    7.2.2 Ergotamines

    Market Estimates & Forecast by region, 2020-2027

    Market Estimates & Forecast country, 2020-2027

    7.2.3 NSAIDS

    Market Estimates & Forecast by region, 2020-2027

    Market Estimates & Forecast country, 2020-2027

    7.2.4 Antiemetics

    Market Estimates & Forecast by region, 2020-2027

    Market Estimates & Forecast country, 2020-2027

    7.2.5 Narcotic Analgesics

    Market Estimates & Forecast by region, 2020-2027

    Market Estimates & Forecast country, 2020-2027

    7.2.6 Others

    7.3 Preventive Treatment

    7.3.1 Antidepressants

    Market Estimates & Forecast by region, 2020-2027

    Market Estimates & Forecast country, 2020-2027

    7.3.2 Botox Injections

    Market Estimates & Forecast by region, 2020-2027

    Market Estimates & Forecast country, 2020-2027

    7.3.3 Others

    Chapter 8. Global Hemplegic Migraine Market, by Distribution Channel

    8.1 Introduction

    8.2 Retail Pharmacies

    Market Estimates & Forecast by region, 2020-2027

    Market Estimates & Forecast country, 2020-2027

    8.3 Hospital Pharmacies

    Market Estimates & Forecast by region, 2020-2027

    Market Estimates & Forecast country, 2020-2027

    8.4 Online Pharmacies

    Market Estimates & Forecast by region, 2020-2027

    Market Estimates & Forecast country, 2020-2027

    Chapter 9. Global Hemplegic Migraine Market, by End User

    9.1 Introduction

    9.2 Hospital & Clinics

    Market Estimates & Forecast by region, 2020-2027

    Market Estimates & Forecast country, 2020-2027

    9.3 Diagnostic Centers

    Market Estimates & Forecast by region, 2020-2027

    Market Estimates & Forecast country, 2020-2027

    9.4 Others

    Chapter 10. Global Hemplegic Migraine Market, by Region

    10.1 Introduction

    10.2 Americas

    10.2.1 North America

    10.2.1.1 US

    10.2.1.2 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 UK

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 Republic of Korea

    10.4.6 Rest of Asia Pacific

    10.5 The Middle East & Africa

    10.5.1 The Middle East

    10.5.2 Africa

    Chapter 11. Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    Chapter 12. Company Profiles

    12.1 Abbott Laboratories

    12.1.1 Company Overview

    12.1.2 Product Overview

    12.1.3 Financials Overview

    12.1.4 Key Developments

    12.1.5 SWOT Analysis

    12.2 Allergen

    12.2.1 Company Overview

    12.2.2 Product Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 AstraZeneca

    12.3.1 Company Overview

    12.3.2 Product Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Eisai Co., Ltd.

    12.4.1 Company Overview

    12.4.2 Business Segment Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 Endo International Plc.

    12.5.1 Company Overview

    12.5.2 Product Overview

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.5.5 SWOT Analysis

    12.6 GlaxoSmithKline Plc.

    12.6.1 Company Overview

    12.6.2 Product Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.6.5 SWOT Analysis

    12.7 Impax Laboratories

    12.7.1 Overview

    12.7.2 Product Overview

    12.7.3 Financial Overview

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 Eli Lily and Company

    12.8.1 Overview

    12.8.2 Product Overview

    12.8.3 Financial Overview

    12.8.4 Key Developments

    12.8.5 SWOT Analysis

    12.9 Johnson & Johnson

    12.9.1 Overview

    12.9.2 Product Overview

    12.9.3 Financial Overview

    12.9.4 Key Developments

    12.9.5 SWOT Analysis

    12.10 Merck & Co.

    12.10.1 Overview

    12.10.2 Product Overview

    12.10.3 Financial Overview

    12.10.4 Key Developments

    12.10.5 SWOT Analysis

    12.11 Others

    Chapter 13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s View Point

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Prediction of the Renal Denervation Industry

    Chapter 14 Appendix

    LIST OF TABLES

    Table 1 Global Hemplegic Migraine Market Synopsis, 2020-2027

    Table 2 Global Hemplegic Migraine Market Estimates and Forecast, 2020-2027, (USD Million)

    Table 3 Global Hemplegic Migraine Market, by Region, 2020-2027, (USD Million)

    Table 4 Global Hemplegic Migraine Market, by Type, 2020-2027, (USD Million)

    Table 5 Global Hemplegic Migraine Market, By Treatment, 2020-2027, (USD Million)

    Table 6 Global Hemplegic Migraine Market, By Treatment, 2020-2027, (USD Million)

    Table 7 Global Hemplegic Migraine Market, by End User, 2020-2027, (USD Million)

    Table 8 North America Global Hemplegic Migraine Market, by Type, 2020-2027, (USD Million)

    Table 9 North America Global Hemplegic Migraine Market, By Treatment, 2020-2027,

    (USD Million)

    Table 10 North America Global Hemplegic Migraine Market, by Distribution Channel, 2020-2027,

    (USD Million)

    Table 11 North America Global Hemplegic Migraine Market, by End User, 2020-2027,

    (USD Million)

    Table 12 US Hemplegic Migraine Market, by Type, 2020-2027, (USD Million)

    Table 13 US Hemplegic Migraine Market, By Treatment, 2020-2027, (USD Million)

    Table 14 US Hemplegic Migraine Market, by Distribution Channel, 2020-2027, (USD Million)

    Table 15 US Hemplegic Migraine Market, by End User, 2020-2027, (USD Million)

    Table 16 Canada Hemplegic Migraine Market,by Type, 2020-2027, (USD Million)

    Table 17 Canada Hemplegic Migraine Market, By Treatment, 2020-2027, (USD Million)

    Table 18 Canada Hemplegic Migraine Market,by Distribution Channel, 2020-2027, (USD Million)

    Table 19 Canada Hemplegic Migraine Market,by End User, 2020-2027, (USD Million)

    Table 20 South America Hemplegic Migraine Market, by Type, 2020-2027, (USD

    Million)

    Table 21 South America Hemplegic Migraine Market, By Treatment, 2020-2027, (USD

    Million)

    Table 22 South America Hemplegic Migraine Market, by Distribution Channel, 2020-2027, (USD

    Million)

    Table 23 South America Hemplegic Migraine Market, by End User, 2020-2027, (USD

    Million)

    Table 24 Europe Hemplegic Migraine Market, by Type, 2020-2027, (USD Million)

    Table 25 Europe Hemplegic Migraine Market, By Treatment, 2020-2027, (USD Million)

    Table 26 Europe Hemplegic Migraine Market, by Distribution Channel, 2020-2027, (USD Million)

    Table 27 Europe Hemplegic Migraine Market, by End User, 2020-2027, (USD Million)

    Table 28 Western Europe Hemplegic Migraine Market, by Type, 2020-2027, (USD

    Million)

    Table 29 Western Europe Hemplegic Migraine Market, By Treatment, 2020-2027, (USD

    Million)

    Table 30 Western Europe Hemplegic Migraine Market, by Distribution Channel, 2020-2027,

    (USD Million)

    Table 31 Western Europe Hemplegic Migraine Market, by End User, 2020-2027,

    (USD Million)

    Table 32 Eastern Europe Hemplegic Migraine Market, by Type, 2020-2027, (USD

    Million)

    Table 33 Eastern Europe Hemplegic Migraine Market, By Treatment, 2020-2027, (USD

    Million)

    Table 34 Eastern Europe Hemplegic Migraine Market, by Distribution Channel, 2020-2027, (USD

    Million)

    Table 35 Eastern Europe Hemplegic Migraine Market, by End User, 2020-2027, (USD

    Million)

    Table 36 Asia Pacific Hemplegic Migraine Market, by Type, 2020-2027, (USD

    Million)

    Table 37 Asia Pacific Hemplegic Migraine Market, By Treatment, 2020-2027, (USD

    Million)

    Table 38 Asia Pacific Hemplegic Migraine Market, by Distribution Channel, 2020-2027, (USD

    Million)

    Table 39 Asia Pacific Hemplegic Migraine Market, by End User, 2020-2027, (USD

    Million)

    Table 40 Middle East & Africa Hemplegic Migraine Market, by Type, 2020-2027, (USD

    Million)

    Table 41 Middle East & Africa Hemplegic Migraine Market, By Treatment, 2020-2027,

    (USD Million)

    Table 42 Middle East & Africa Hemplegic Migraine Market, by Distribution Channel, 2020-2027,

    (USD Million)

    Table 43 Middle East & Africa Hemplegic Migraine Market, by End User, 2020-2027,

    (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Hemplegic Migraine Market

    Figure 3 Segmentation Market Dynamics for Global Hemplegic Migraine Market

    Figure 4 Global Hemplegic Migraine Market Share, by Type 2020

    Figure 5 Global Hemplegic Migraine Market Share, By Treatment, 2020

    Figure 6 Global Hemplegic Migraine Market Share, by Distribution Channel, 2020

    Figure 7 Global Hemplegic Migraine Market Share, by End User, 2020

    Figure 8 Global Hemplegic Migraine Market Share, by Region, 2020

    Figure 9 North America Hemplegic Migraine Market Share, by Country, 2020

    Figure 10 Europe Hemplegic Migraine Market Share, by Country, 2020

    Figure 11 Asia Pacific Hemplegic Migraine Market Share, by Country, 2020

    Figure 12 Middle East & Africa Hemplegic Migraine Market Share, by Country, 2020

    Figure 13 Global Hemplegic Migraine Market: Company Share Analysis, 2020 (%)

    Figure 14 Abbott Laboratories: Key Financials

    Figure 15 Abbott Laboratories: Segmental Revenue

    Figure 16 Abbott Laboratories: Geographical Revenue

    Figure 17 Allergen: Key Financials

    Figure 18 Allergen: Segmental Revenue

    Figure 19 Allergen: Geographical Revenue

    Figure 20 AstraZeneca::Key Financials

    Figure 21 AstraZeneca: Segmental Revenue

    Figure 22 AstraZeneca: Geographical Revenue

    Figure 23 Eisai Co., Ltd.: Key Financials

    Figure 24 Eisai Co., Ltd.: Segmental Revenue

    Figure 25 Eisai Co., Ltd.: Geographical Revenue

    Figure 26 Endo International Plc.:Key Financials

    Figure 27 Endo International Plc.: Segmental Revenue

    Figure 28 Endo International Plc.. Geographical Revenue

    Figure 29 GlaxoSmithKline Plc.: Key Financials

    Figure 30 GlaxoSmithKline Plc.: Segmental Revenue

    Figure 31 GlaxoSmithKline Plc.: Geographical Revenue

    Figure 32 Impax Laboratories: Key Financials

    Figure 33 Impax Laboratories: Segmental Revenue

    Figure 34 Impax Laboratories: Geographical Revenue

    Figure 35 Eli Lily and Company: Segmental Revenue

    Figure 36 Eli Lily and Company: Geographical Revenue

    Figure 37 Eli Lily and Company: Key Financials

    Figure 38 Johnson & Johnson: Segmental Revenue

    Figure 39 Johnson & Johnson: Geographical Revenue

    Figure 40 Johnson & Johnson: Key Financials

    Figure 41 Merck & Co.: Segmental Revenue

    Figure 42 Merck & Co.: Geographical Revenue

    Figure 43 Merck & Co.: Key Financials



    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.